Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/09/2010US7829276 Using conditionally replication-competent adenoviruses transcription as diagnostic indicator of cell proliferative disorders of alimentary canal; tissue targeted therapy; drug delivery
11/09/2010US7829124 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/09/2010US7829095 Produced by hybridoma cell line DSM ACC 2533
11/09/2010US7829092 Recombinant anti-VLA4 antibody molecules
11/09/2010US7829090 Human antibody molecules for IL-13
11/09/2010US7829064 antigen binding molecules conjugated to lipids, polymer carriers, micelles, nanoparticles or mixtures and effectors, used for therapy of diagnosis
11/09/2010CA2496164C Benzimidazole quinolinones and uses thereof
11/09/2010CA2488279C Anti-inflammatory compositions derived from chicory
11/09/2010CA2462692C Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
11/09/2010CA2434937C Phenyl derivatives
11/09/2010CA2434028C Amino ceramide-like compounds and therapeutic methods of use
11/09/2010CA2412493C Purging of cells using viruses
11/09/2010CA2407659C Growth hormone secretagogues
11/09/2010CA2393487C Pharmaceutical preparation for the treatment of oncoses
11/09/2010CA2386242C Tumour-specific vector for gene therapy
11/09/2010CA2380070C New derivatives of hydantoines, thiohydantoine, pyrimidinediones and thioxopyrimidinones, their preparation methods and their application as medications
11/09/2010CA2362794C Inhibitors of separase, method for identifying them and uses
11/09/2010CA2343102C Antisense modulation of survivin expression
11/09/2010CA2326654C Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
11/09/2010CA2223532C Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions
11/04/2010WO2010127363A1 Toposiomerase inhibitors
11/04/2010WO2010127360A1 Toposiomerase inhibitors
11/04/2010WO2010127235A1 Schweinfurthins and uses thereof
11/04/2010WO2010127190A1 Salt of abt-263 and solid-state forms thereof
11/04/2010WO2010126895A1 Inhibitors of pi3 kinase and / or mtor
11/04/2010WO2010126888A1 Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
11/04/2010WO2010126452A1 Molecular signature of human lung cancer initiating cells and uses thereof
11/04/2010WO2010126435A1 Novel galactoside inhibitors of galectins
11/04/2010WO2010126279A2 Cytokeratin 17-specific human antibody
11/04/2010WO2010126179A1 Pharmaceutical composition comprising chlorine e6-folic acid conjugated compound and chitosan for treatment of cancer
11/04/2010WO2010126167A1 Thiophene derivative
11/04/2010WO2010126104A1 4-substituted pyridazinone compound and p2x7 receptor inhibitor
11/04/2010WO2010126102A1 Scca-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient
11/04/2010WO2010126101A1 Purine derivative and antitumor agent using same
11/04/2010WO2010126074A1 Pharmaceutical composition for maintenance therapy which contains antibody capable of recognizing hla class-i as active ingredient
11/04/2010WO2010126073A1 Expression cassette for secretion/expression of polypeptide, and use thereof
11/04/2010WO2010126066A1 Anti-il-3rα antibody for use in treatment of blood tumor
11/04/2010WO2010126036A1 Combined drug
11/04/2010WO2010126034A1 Novel compound, histone acetylase inhibitor, nuclear receptor transcription activation inhibitor, deuteromycetes belonging to genus penicillium, and production process
11/04/2010WO2010125799A1 Urea derivative having pi3k inhibitory activity
11/04/2010WO2010125647A1 Radioactively labeled substance
11/04/2010WO2010125402A1 Imidazole derivatives and their use as modulators of cyclin dependent kinases
11/04/2010WO2010125350A1 Treatment or prophylaxis of proliferative conditions
11/04/2010WO2010125343A1 Compounds for inducing cellular apoptosis
11/04/2010WO2010125107A1 Microglial precursor cells for the treatment of malignant neoplasms of the central nervous system
11/04/2010WO2010125082A1 Oxazole substituted indazoles as pi3-kinase inhibitors
11/04/2010WO2010125004A1 Cdk inhibitor salts
11/04/2010WO2010124826A1 Substituted imidazoquinoxalines
11/04/2010WO2010124797A1 Anti-mesothelin immunoconjugates and uses therefor
11/04/2010WO2010124654A1 Vascular embolus of sodium alginate microspheres comprising drug for resisting hemangioma, preparation method, and use thereof
11/04/2010WO2010124648A1 Azaazulene compounds
11/04/2010WO2010124547A1 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
11/04/2010WO2010124525A1 Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
11/04/2010WO2010124522A1 Arsenic compounds, their preparation methods and uses thereof
11/04/2010WO2010124521A1 Derivatives of rhein, preparation methods and uses thereof
11/04/2010WO2010124520A1 Pharmaceutical composition for treating abnormal energy metabolism and use thereof
11/04/2010WO2010124498A1 A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine
11/04/2010WO2010124393A1 Anticancer agent comprising a yatapoxvirus mutant and uses thereof
11/04/2010WO2010124361A1 Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
11/04/2010WO2010124322A1 Bicarbonate solution for bioavailable magnesium and uses thereof
11/04/2010WO2010103405A3 Process for preparing cephalotaxine esters
11/04/2010WO2010084157A3 Multifunctional stealth nanoparticles for biomedical use
11/04/2010WO2010083404A3 Linked myc-max small molecule inhibitors
11/04/2010WO2010083215A3 Composition and method for the treatment of diseases affected by apoptosis
11/04/2010WO2010081173A3 Modified antibody compositions, methods of making and using thereof
11/04/2010WO2010080769A3 Chemotherapeutic methods and compositions
11/04/2010WO2010080570A3 Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
11/04/2010WO2010080414A3 Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
11/04/2010WO2010079850A3 Agent for prophylaxis or treatment of cancer
11/04/2010WO2010077310A3 Amide derivatives of ethacrynic acid
11/04/2010WO2010061208A3 Combination comprising a quinazoline derivative and a taxane
11/04/2010WO2009117080A8 Quinazoline derivatives as raf kinase modulators and methods of use thereof
11/04/2010US20100280452 Medical devices having multiple layers
11/04/2010US20100280249 Synthesis of 4-amino-thalidomide enantiomers
11/04/2010US20100280232 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
11/04/2010US20100280177 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
11/04/2010US20100280134 Markers for Bladder Cancer Detection
11/04/2010US20100280125 Medicinal agent
11/04/2010US20100280112 Composition Enriched in Diglyceride with Conjugated Linoleic Acid
11/04/2010US20100280108 Antitumoral Compounds
11/04/2010US20100280105 Detection of mage-a expression
11/04/2010US20100280102 Double-stranded ribonucleic acid with increased effectiveness in an organism
11/04/2010US20100280101 Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
11/04/2010US20100280097 Compositions comprising hif-1 alpha sirna and methods of use thereof
11/04/2010US20100280087 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
11/04/2010US20100280084 Cyp1B1 Genotype
11/04/2010US20100280076 Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
11/04/2010US20100280075 Paclitaxel enhancer compounds
11/04/2010US20100280070 Novel tetrahydroquinolines as aromatase inhibitors
11/04/2010US20100280065 Perharidines as cdk inhibitors
11/04/2010US20100280063 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
11/04/2010US20100280060 Methods of screening and compositions for life span modulators
11/04/2010US20100280056 Identification of subjects likely to benefit from statin therapy
11/04/2010US20100280049 Antagonists of pgd2 receptors
11/04/2010US20100280048 Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
11/04/2010US20100280046 Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
11/04/2010US20100280045 Novel compounds
11/04/2010US20100280043 Pyrazolopyridines as kinase inhibitors
11/04/2010US20100280042 Quinazoline derivatives for the treatment of tumours
11/04/2010US20100280037 Crystalline form of a dihydropteridione derivative
1 ... 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 ... 2211